This study suggests that GLP-1RAs could be promising new therapeutic agents for obese asthma patients, particularly due to their impact on the expression of IL-1 modulated by nucleotide oligomerization domain-like receptor protein 3 (NLRP3) [249]
The same applies to those facing weight loss plateaus on tirzepatide or experiencing no results after 4 weeks on semaglutide
The move was intended to rapidly improve treatment accessibility
Patients taking tirzepatide may show: Improved glycemic markers : Lower fasting glucose and reduced hemoglobin A1c levels Potential lipid profile changes : Possible decreases in triglycerides and changes in cholesterol parameters Liver function parameters : Possible changes in liver enzymes in patients with fatty liver disease Kidney function monitoring : Serum creatinine and estimated glomerular filtration rate should be tracked, particularly if dehydration occurs It is important to note that tirzepatide has no known interference with standard laboratory assays and is not included in standard drug screening tests, which typically focus on substances of abuse and controlled medications
Medical professionals must educate patients about potential injection-site reactions and hypersensitivity reactions, which could lead to autoimmune conditions like pyoderma gangrenosum and BP [33,41,73]
Microdosing means taking a lower-than-standard dose of a GLP-1 medication to activate its broader health effects while minimizing side effects like nausea or fatigue
